Lisofylline: A potential lead for the treatment of diabetes

Biochemical Pharmacology

Volumn 69, Issue 1, 2005, Pages 1-5

  Yang, Zandong ^a   Chen, Meng ^a   Nadler, Jerry L ^a  

^a Clinical Virology   (Austria)

Author keywords

Anti inflammation; Autoimmunity; Cytokine; Islet transplantation; Pancreatic cell; Type 1 diabetes

Indexed keywords

CYTOKINE; GAMMA INTERFERON; LISOFYLLINE; PHOSPHATIDIC ACID; STAT4 PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL FUNCTION; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; MOLECULAR MECHANICS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 9944249163     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.08.012     Document Type: Note

References (63)

1. J.A. Lillibridge, T.F. Kalhorn, and J.T. Slattery Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol Drug Metab. Dispos. 24 1996 1174 1179
2. S.L. Bursten, D. Federighi, J. Wald, B. Meengs, W. Spickler, and E. Nudelman Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids J. Pharmacol. Exp. Ther. 284 1998 337 345
3. H.S. Shin, and J.T. Slattery CYP3A4-mediated oxidation of lisofylline to lisofylline 4,5-diol in human liver microsomes J. Pharm. Sci. 87 1998 390 393
4. G.C. Rice, P.A. Brown, R.J. Nelson, J.A. Bianco, J.W. Singer, and S. Bursten Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid Proc. Natl. Acad. Sci. USA 91 1994 3857 3861
5. S. Bursten, R. Weeks, J. West, T. Le, T. Wilson, and D. Porubek Potential role for phosphatidic acid in mediating the inflammatory responses to TNF α and IL-1β Circ. Shock 44 1994 14 29
6. D. Bleich, S. Chen, S.L. Bursten, and J.L. Nadler Lisofylline, an inhibitor of unsaturated phosphatidic acid generation, ameliorates interleukin-lβ-induced dysfunction in cultured rat islets Endocrinology 137 1996 4871 4877
7. D.A. Pan, S. Lillioja, M.R. Milner, A.D. Kriketos, L.A. Baur, and C. Bogardus Skeletal muscle membrane lipid composition is related to adiposity and insulin action J. Clin. Invest. 96 1995 2802 2808
8. L.H. Storlien, D.A. Pan, A.D. Kriketos, J. O'Connor, I.D. Caterson, and G.J. Cooney Skeletal muscle membrane lipids and insulin resistance Lipids 31 Suppl 5 1996
9. J.M. Kremer Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids Lipids 31 Suppl 7 1996
10. S.L. Bursten, D.A. Federighi, P. Parsons, W.E. Harris, E. Abraham, and E.E. Moore An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndrome Crit. Care Med. 24 1996 1129 1136
11. C.L. George, G. Fantuzzi, S. Bursten, L. Leer, and E. Abraham Effects of lisofylline on hyperoxia-induced lung injury Am. J. Physiol. 276 1999 776 785
12. N. Hasegawa, Y. Oka, M. Nakayama, G.J. Berry, S. Bursten, and G. Rice The effects of post-treatment with lisofylline, a phosphatidic acid generation inhibitor, on sepsis-induced acute lung injury in pigs Am. J. Respir. Crit. Care Med. 155 1997 928 936
13. Y. Oka, N. Hasegawa, M. Nakayama, G.A. Murphy, H.H. Sussman, and T.A. Raffin Selective downregulation of neutrophils by a phosphatidic acid generation inhibitor in a porcine sepsis model J. Surg. Res. 81 1999 147 155
14. D.M. Guidot, S.L. Bursten, G.C. Rice, R.B. Chaney, J.W. Singer, and A.J. Repine Modulating phosphatidic acid metabolism decreases oxidative injury in rat lungs Am. J. Physiol. 273 1997 966 967
15. K. Waxman, K. Daughters, S. Aswani, and G. Rice Lisofylline decreases white cell adhesiveness and improves survival after experimental hemorrhagic shock Crit. Care Med. 24 1996 1724 1728
16. S. Wattanasirichaigoon, M.J. Menconi, R.L. Delude, and M.P. Fink Lisofylline ameliorates intestinal mucosal barrier dysfunction caused by ischemia and ischemia/reperfusion Shock 11 1999 269 275
17. S. Wattanasirichaigoon, M.J. Menconi, and M.P. Fink Lisofylline ameliorates intestinal and hepatic injury induced by hemorrhage and resuscitation in rats Crit. Care Med. 28 2000 1540 1549
18. M. Chen, Z. Yang, R. Wu, and J.L. Nadler Lisofylline, a novel anti-inflammatory agent, protects pancreatic β-cells from pro-inflammatory cytokine damage by promoting mitochondrial metabolism Endocrinology 143 2002 2341 2348
19. E. Clarke, G.C. Rice, R.S. Weeks, N. Jenkins, R. Nelson, and J.A. Bianco Lisofylline inhibits transforming growth factor beta release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice Cancer Res. 56 1996 105 112
20. A. Husain, N. Rosales, G.K. Schwartz, and D.R. Spriggs Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II) Gynecol. Oncol. 70 1998 17 22
21. P. de Vries, and J.W. Singer Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents Exp Hematol 28 2000 916 923
22. J.S. Wong, G. Ara, S.R. Keyes, R. Herbst, C.N. Coleman, and B.A. Teicher Lisofylline as a modifier of radiation therapy Oncol. Res. 8 1996 513 518
23. A.F. List, R. Maziarz, P. Stiff, J. Jansen, J. Liesveld, and F. Andrews A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The lisofylline marrow transplant study group Bone Marrow Transplant 25 2000 283 291
24. G.C. Rice, J. Rosen, R. Weeks, J. Michnick, S. Bursten, and J.A. Bianco CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo Shock 1 1994 254 266
25. A.M. van Furth, E.M. Verhard-Seijmonsbergen, R. van Furth, and J.A. Langermans Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-α, IL-β, IL-10 by human leucocytes Immunology 91 1997 193 196
26. C. Du, J.C. Cooper, S.J. Klaus, and S. Sriram Amelioration of CR-EAE with lisofylline: effects on mRNA levels of IL-12 and IFN-γ in the CNS J. Neuroimmunol. 110 2000 13 19
27. G. Trinchieri Interleukin-12: a pro-inflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity Annu. Rev. Immunol. 13 1995 251 276
28. W.E. Thierfelder, J.M. van Deursen, K. Yamamoto, R.A. Tripp, S.R. Sarawar, and R.T. Carson Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells Nature 382 1996 171 174
29. M.H. Kaplan, Y.L. Sun, T. Hoey, and M.J. Grusby Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice Nature 382 1996 174 177
30. S. Trembleau, G. Penna, E. Bosi, A. Mortara, M.K. Gately, and L. Adorini Interleukin-12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice J. Exp. Med. 181 1995 817 821
31. M.F. Neurath, I. Fuss, B.L. Kelsall, E. Stuber, and W. Strober Antibodies to interleukin 12 abrogate established experimental colitis in mice J. Exp. Med. 182 1995 1281 1290
32. J.J. Bright, C. Du, M. Coon, S. Sriram, and S.J. Klaus Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signalling and IL-12-mediated Thl differentiation: an effect of the novel anti-inflammatory drug lisofylline J. Immunol. 161 1998 7015 7022
33. M.E. Coon, M. Diegel, N. Leshinsky, and S.J. Klaus Selective pharmacologic inhibition of murine and human IL-12-dependent Thl differentiation and IL-12 signalling J. Immunol. 163 1999 6567 6574
34. Z. Yang, M. Chen, L.B. Fialkow, J.D. Ellett, R. Wu, and J.L. Nadler Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes Ann. NY Acad. Sci. 1005 2003 409 411
35. S. Makino, K. Kunimoto, Y. Muraoka, Y. Mizushima, K. Katagiri, and Y. chino Breeding of a non-obese, diabetic strain of mice Jikken Dobutsu. Exp. Anim. 29 1980 1 13
36. H. Kikutani, and S. Makino The murine autoimmune diabetes model: NOD and related strains Adv. Immunol. 51 1992 285 322
37. Z.D. Yang, M. Chen, R. Wu, M. McDuffie, and J.L. Nadler The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice Diabetologia 45 2002 1307 1314
38. S.W. Christianson, L.D. Shultz, and E.H. Leiter Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD. NON-Thy-la donors Diabetes 42 1993 44 55
39. M.S. Choi, R. Ray, Z. Zhang, and A.B. Mukherjee IFN-γ stimulates the expression of a novel Secretoglobin that regulates chemotactic cell migration and invasion J. Immunol. 172 2004 4245 4252
40. Z. Yang, M. Chen, L.B. Fialkow, J.D. Ellett, R. Wu, and J.L. Nadler The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice Pancreas 26 2003 e99 104
41. A.A. Like, and A.A. Rossini Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus Science 193 1976 415 417
42. G. Brosky, and J. Logothetopoulos Streptozotocin diabetes in the mouse and guinea pig Diabetes 18 1969 606 611
43. K.C. Herold, T.N. Bloch, V. Vezys, and Q. Sun Diabetes induced with low doses of streptozotocin is mediated by V beta 8.2+ T-cells Diabetes 44 1995 354 359
44. I.L. Campbell, L. Oxbrow, M. Koulmanda, and L.C. Harrison IFN-gamma induces islet cell MHC antigens and enhances autoimmune, streptozotocin-induced diabetes in the mouse J. Immunol. 140 1988 1111 1116
45. Z. Yang, M. Chen, J.D. Ellett, L.B. Fialkow, J.D. Carter, and M. McDuffie Autoimmune diabetes is blocked in Stat4-deficient mice J. Autoimmun. 22 2004 191 200
46. Z. Yang, M. Chen, J.D. Carter, K.M. Smith, K.L. Brayman, and J.L. Nadler Inflammatory blockade improves human islet function in transplantation Diabetes 53 Suppl 2 2004 455
47. S. Desagher, and J.C. Martinou Mitochondria as the central control point of apoptosis Trends Cell Biol. 10 2000 369 377
48. C.B. Wollheim β-cell mitochondria in the regulation of insulin secretion: a new culprit in Type II diabetes Diabetologia 43 2000 265 277
49. M.D. Stegall, K.J. Lafferty, I. Kam, and R.G. Gill Evidence of recurrent autoimmunity in human allogeneic islet transplantation Transplantation 61 1996 1272 1274
50. T. Pearson, T.G. Markees, D.V. Serreze, M.A. Pierce, L.S. Wicker, and L.B. Peterson Islet cell autoimmunity and transplantation tolerance: two distinct mechanisms? Ann. NY Acad. Sci. 1005 2003 148 156
51. D.S. Wilkes The role of autoimmunity in the pathogenesis of lung allograft rejection Archivum Immunologiae et Therapiae Experimentalis 51 2003 227 230
52. D. Vergani, and G. Mieli-Vergani Autoimmunity after liver transplantation Hepatology 36 2002 271 276
53. T. Bednarczuk, U. Makowska, and J. Nauman Development of Graves' disease in a patient under immunosuppressive therapy after liver transplantation J. Endocrinol. Invest. 26 2003 257 260
54. M. Hurtova, J.C. Duclos-Vallee, C. Johanet, J.F. Emile, A.M. Roque-Afonso, and C. Feray Successful tacrolimus therapy for a severe recurrence of Type 1 autoimmune hepatitis in a liver graft recipient Liver Transpl. 7 2001 556 558
55. A. Boker, L. Rothenberg, C. Hernandez, N.S. Kenyon, C. Ricordi, and R. Alejandro Human islet transplantation: update World J. Surg. 25 2001 481 486
56. P. Petruzzo, F. Andreelli, B. McGregor, N. Lefrancois, M. Dawahra, and L.C. Feitosa Evidence of recurrent Type I diabetes following HLA-mismatched pancreas transplantation Diabetes Metab. 26 2000 215 218
57. J. Oberholzer, F. Triponez, R. Mage, E. Andereggen, L. Buhler, and N. Cretin Human islet transplantation: lessons from 13 autologous and 13 allogeneic transplantations Transplantation 69 2000 1115 1123
58. T. Lohmann, C. List, P. Lamesch, K. Kohlhaw, M. Wenzke, and C. Schwarz Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506/tacrolimus Exp. Clin. Endocrinol. Diabetes 108 2000 347 352
59. Z. Yang, M. Chen, J.D. Ellett, L.B. Fialkow, J.D. Carter, and J.L. Nadler The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation Transplantation 77 2004 55 60
60. D.T. Bolick, M.E. Hatley, S. Srinivasan, C.C. Hedrick, and J.L. Nadler Lisofylline a novel anti-inflammatory compound, protects mesangial cells from hyperglycemia-and angiotensin II-mediated extracellular matrix deposition Endocrinology 144 2003 5227 5231
61. S.V. McLennan, A.K. Death, E.J. Fisher, P.F. Williams, D.K. Yue, and J.R. Turtle The role of the mesangial cell and its matrix in the pathogenesis of diabetic nephropathy Cell. Mol. Biol. 45 1999 123 135
62. H.W. Schnaper, T. Hayashida, S.C. Hubchak, and A.C. Poncelet TGF-beta signal transduction and mesangial cell fibrogenesis Am. J. Physiol. Renal Fluid Electrolyte Physiol. 284 2003 243 252
63. M.A. Reddy, S.G. Adler, Y.S. Kim, L. Lanting, J. Rossi, and S.W. Kang Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells Am. J. Physiol. Renal Fluid Electrolyte Physiol. 283 2002 985 994